Barrett's esophagus: pathogenesis, treatment, and prevention

Gastrointest Endosc Clin N Am. 2008 Jul;18(3):495-512, ix. doi: 10.1016/j.giec.2008.05.005.

Abstract

Esophageal adenocarcinoma is the most common type of esophageal cancer seen in the United States and Western Europe. Barrett's esophagus (BE) is a well-known risk factor for esophageal adenocarcinoma and is believed to be found in 6% to 12% of patients undergoing endoscopy for gastroesophageal reflux disease and in more than 1% of all patients undergoing endoscopy. This article focuses on the pathogenesis, treatment, and prevention of BE.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Barrett Esophagus / drug therapy
  • Barrett Esophagus / physiopathology*
  • Barrett Esophagus / prevention & control
  • Barrett Esophagus / surgery*
  • Esophagoscopy*
  • Humans
  • Prognosis